Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP, International Markets | March 04, 2021 | March 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date March 04, 2021 · Filed March 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2021-03-04 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-03-04 · Grant · Acquired 12,935 · Balance 12,935 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Row 2 · 2021-03-04 · Sale · Disposed 12,935 · Balance 0 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.700, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 25,870 |
Reported balance
After 2021-03-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-04 · Exercise / conversion · Disposed 12,935 · Balance 25,870 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5: Restricted share units were granted on March 4, 2019, with 12,935 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.700, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: Restricted share units were granted on March 4, 2019, with 12,935 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2021 Filed Mar 8, 2021 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 12,935 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018524 · doc4.xml · derivative · entry 3 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,870 Underlying: Ordinary Shares · 12,935 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 12,935 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 12,935 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 12,935 | $10.58 | $136,909.21 |
DisclosureSEC source: 0001209191-21-018524 · doc4.xml · nonDerivative · entry 2 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.700, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantOrdinary Shares | 12,935 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-018524 · doc4.xml · nonDerivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,935 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017761 · doc4.xml · derivative · entry 3 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F5 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,400 | $10.88 | $15,231.44 |
DisclosureSEC source: 0001209191-21-017761 · doc4.xml · nonDerivative · entry 2 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.840 to $10.915, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-017761 · doc4.xml · nonDerivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 60,410.357 | $10.88 | $657,240.52 |
DisclosureSEC source: 0001209191-21-015847 · doc4.xml · nonDerivative · entry 3 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.84 to $10.91, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 15,177 | $10.85 | $164,684.11 |
DisclosureSEC source: 0001209191-21-015847 · doc4.xml · nonDerivative · entry 2 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,410.357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.775 to $11.005, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 15,177 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015847 · doc4.xml · derivative · entry 4 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,534 Underlying: Ordinary Shares · 15,177 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 15,177 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 15,180 vesting on February 28, 2024. F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 15,177 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 15,180 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,177 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-015847 · doc4.xml · nonDerivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,587.357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 11,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009637 · doc4.xml · derivative · entry 5 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,941 Underlying: Ordinary Shares · 11,941 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 11,941 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F8 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 11,941 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 17,480 | $12.72 | $222,361.33 |
DisclosureSEC source: 0001209191-21-009637 · doc4.xml · nonDerivative · entry 4 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,410.357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 4,155 | $12.72 | $52,855.34 |
DisclosureSEC source: 0001209191-21-009637 · doc4.xml · nonDerivative · entry 3 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,890.357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantOrdinary Shares | 50,260 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009637 · doc4.xml · nonDerivative · entry 2 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,045.357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units. F4 · price: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 11,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009637 · doc4.xml · nonDerivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,785.357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 874 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020164 · doc4.xml · derivative · entry 3 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 872 vesting on each of March 17, 2018 and March 17, 2019 and 874 vesting on March 17, 2020. F6 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 872 vesting on each of March 17, 2018 and March 17, 2019 and 874 vesting on March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 345 | $7.17 | $2,474.13 |
DisclosureSEC source: 0001209191-20-020164 · doc4.xml · nonDerivative · entry 2 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,844.357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.2000, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 874 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-020164 · doc4.xml · nonDerivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,189.357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 13:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016460 · doc4.xml · derivative · entry 3 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Ordinary Shares · 1,399 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 13:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 548 | $11.77 | $6,447.60 |
DisclosureSEC source: 0001209191-20-016460 · doc4.xml · nonDerivative · entry 2 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,315.357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.7300 to $11.8100, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 13:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,399 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-016460 · doc4.xml · nonDerivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,863.357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 12:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 60,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014852 · doc4.xml · derivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, International Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,711 Underlying: Ordinary Shares · 60,711 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 15,177 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 15,180 vesting on February 28, 2024. F2 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 15,177 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 15,180 vesting on February 28, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 12:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 4,155 | $12.24 | $50,864.26 |
DisclosureSEC source: 0001209191-20-008165 · doc4.xml · nonDerivative · entry 2 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,464.357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.2400 to $12.2450, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2020 Filed Feb 11, 2020 12:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 11,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008165 · doc4.xml · derivative · entry 3 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,882 Underlying: Ordinary Shares · 11,941 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 11,941 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F6 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 11,941 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2020 Filed Feb 11, 2020 12:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 11,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-008165 · doc4.xml · nonDerivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,619.357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050265 · doc4.xml · derivative · entry 3 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,638 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on September 18, 2017, with 2,638 vesting on each of September 18, 2018 and September 18, 2019. F5 · derivative.expiration_date: Restricted share units were granted on September 18, 2017, with 2,638 vesting on each of September 18, 2018 and September 18, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 962 | $7.82 | $7,523.13 |
DisclosureSEC source: 0001209191-19-050265 · doc4.xml · nonDerivative · entry 2 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,678.357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.81 to $7.84, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-050265 · doc4.xml · nonDerivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,640.357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 12:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 320 | $16.64 | $5,326.27 |
DisclosureSEC source: 0001209191-19-020162 · doc4.xml · nonDerivative · entry 2 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,002.357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $ 16.6400 to $16.6516, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 872 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-020162 · doc4.xml · derivative · entry 3 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 874 Underlying: Ordinary Shares · 872 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 872 vesting on each of March 17, 2018 and March 17, 2019 and 874 vesting on March 17, 2020. F5 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 872 vesting on each of March 17, 2018 and March 17, 2019 and 874 vesting on March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 872 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-020162 · doc4.xml · nonDerivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,322.357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 11:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 883 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-019330 · doc4.xml · derivative · entry 3 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 12, 2015, with 880 vesting on March 12, 2018 and 883 vesting on March 12, 2019. F5 · derivative.expiration_date: Restricted share units were granted on March 12, 2015, with 880 vesting on March 12, 2018 and 883 vesting on March 12, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 11:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 325 | $15.69 | $5,099.19 |
DisclosureSEC source: 0001209191-19-019330 · doc4.xml · nonDerivative · entry 2 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,450.357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.670 to $15.705, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 11:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 883 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-019330 · doc4.xml · nonDerivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,775.357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 13:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 512 | $16.88 | $8,644.81 |
DisclosureSEC source: 0001209191-19-016097 · doc4.xml · nonDerivative · entry 2 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,892.357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $17.1316, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 12:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 38,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017233 · doc4.xml · derivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,805 Underlying: Ordinary Shares · 38,805 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 12,935 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 12,935 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2019 Filed Mar 5, 2019 13:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016097 · doc4.xml · derivative · entry 3 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,799 Underlying: Ordinary Shares · 1,399 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F5 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2019 Filed Mar 5, 2019 13:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,399 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-016097 · doc4.xml · nonDerivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,404.357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-051778 · doc4.xml · derivative · entry 3 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,638 Underlying: Ordinary Shares · 2,638 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on September 18, 2017, with 2,638 vesting on each of September 18, 2018 and September 18, 2019. F5 · derivative.expiration_date: Restricted share units were granted on September 18, 2017, with 2,638 vesting on each of September 18, 2018 and September 18, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,379 | $23.69 | $32,669.89 |
DisclosureSEC source: 0001209191-18-051778 · doc4.xml · nonDerivative · entry 2 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,005.357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.680 to $23.720, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-051778 · doc4.xml · nonDerivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,384.357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 20:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 457 | $17.89 | $8,176.64 |
DisclosureSEC source: 0001209191-18-020862 · doc4.xml · nonDerivative · entry 2 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,746.357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.87 to $17.92, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 872 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020862 · doc4.xml · derivative · entry 3 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,746 Underlying: Ordinary Shares · 872 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 872 vesting on each of March 17, 2018 and March 17, 2019 and 874 vesting on March 17, 2020. F5 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 872 vesting on each of March 17, 2018 and March 17, 2019 and 874 vesting on March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:11 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 872 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-020862 · doc4.xml · nonDerivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,203.357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:31 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 880 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-019565 · doc4.xml · derivative · entry 3 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 883 Underlying: Ordinary Shares · 880 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 12, 2015, with 880 vesting on March 12, 2018 and 883 vesting on March 12, 2019. F5 · derivative.expiration_date: Restricted share units were granted on March 12, 2015, with 880 vesting on March 12, 2018 and 883 vesting on March 12, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:31 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 461 | $19.50 | $8,988.58 |
DisclosureSEC source: 0001209191-18-019565 · doc4.xml · nonDerivative · entry 2 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,331.357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.49 to $19.5107, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:31 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-019565 · doc4.xml · nonDerivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,792.357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Tax withholdingOrdinary Shares | 732 | $19.28 | $14,112.96 |
DisclosureSEC source: 0001209191-18-017227 · doc4.xml · nonDerivative · entry 2 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,912.357 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 21:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017227 · doc4.xml · derivative · entry 3 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,198 Underlying: Ordinary Shares · 1,399 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 1,399 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,400 vesting on March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 21:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,399 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-017227 · doc4.xml · nonDerivative · entry 1 Nazzi Gianfranco · CIK 0001725018 · EVP, Growth Markets Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,644.357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.